Drug intelligence / Profile preview

PP4 siRNA

Development stage
Preclinical
Lead developer
University of California, Los Angeles
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

PP4 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Protein Phosphatase 4 (PP4), specifically targeting the catalytic subunit PPP4C. PP4 is a serine/threonine phosphatase that plays a critical role in cell cycle progression, centrosome maturation, and DNA damage repair. Research presented at the AACR 2015 conference highlighted PP4 as a potential therapeutic target in BRAF wild-type melanoma, where it is often overexpressed and associated with disease progression and resistance to BRAF and MEK inhibitors. In preclinical studies using human melanoma cell lines, treatment with PP4 siRNA resulted in significant reduction of PP4 protein levels, leading to inhibited cell proliferation, cell cycle arrest, and the induction of apoptosis. This modality represents a targeted approach to treating metastatic melanoma through a BRAF- and MEK-independent pathway.

Other names
Protein phosphatase 4 siRNAPPP4C siRNAPPP-4C siRNAPPP 4C siRNAsiRNA targeting PP4
02

Targets

PPP4C (Serine/threonine-protein phosphatase 4 catalytic subunit)

Beyond the preview

Go deeper on PP4 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP4 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call